BioAtla, Inc. (BCAB)
- Previous Close
0.4287 - Open
0.4250 - Bid 0.3001 x 200
- Ask 0.5224 x 200
- Day's Range
0.4002 - 0.4304 - 52 Week Range
0.2400 - 2.8650 - Volume
222,044 - Avg. Volume
657,164 - Market Cap (intraday)
23.379M - Beta (5Y Monthly) 1.00
- PE Ratio (TTM)
-- - EPS (TTM)
-1.2200 - Earnings Date Aug 6, 2025 - Aug 11, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
8.33
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and squamous cell carcinoma of head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.
www.bioatla.comRecent News: BCAB
View MorePerformance Overview: BCAB
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BCAB
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BCAB
View MoreValuation Measures
Market Cap
23.38M
Enterprise Value
-8.43M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.86
Price/Book (mrq)
42.74
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-65.79%
Return on Equity (ttm)
-246.21%
Revenue (ttm)
11M
Net Income Avi to Common (ttm)
-61.88M
Diluted EPS (ttm)
-1.2200
Balance Sheet and Cash Flow
Total Cash (mrq)
32.36M
Total Debt/Equity (mrq)
101.28%
Levered Free Cash Flow (ttm)
-34.48M